This study involves people with diabetes mellitus who have experienced a myocardial infarction, which is commonly known as a heart attack. After a heart attack, fatty deposits called plaque can build up in the blood vessels that supply the heart, a process called atherosclerosis. This study will look at whether certain diabetes medications can help slow down or stop this plaque buildup. The medications being tested belong to a group called sodium-glucose cotransporter-2 inhibitors, also known as glycosuric agents. These include dapagliflozin (found in the medication Forxiga), empagliflozin (found in the medication Jardiance), and canagliflozin (found in the medication Invokana). All of these medications are taken by mouth as tablets.
The purpose of this study is to see if these diabetes medications can help stabilize or reduce the buildup of plaque in the heart’s blood vessels after a heart attack in people with diabetes. During the study, participants will take one of these medications for 12 months. The study will use a special imaging test called coronary CT angiography, which is a type of scan that takes detailed pictures of the blood vessels in the heart. This scan will be done at the beginning of the study and again after 12 months to measure any changes in the amount of plaque in the blood vessels. The main focus will be on blood vessels that were not treated during the procedure to open blocked arteries, which is called PCI or percutaneous coronary intervention.
Throughout the study, doctors will also look at other health markers including substances in the blood that show inflammation, markers that indicate how well blood sugar is controlled, and features of the plaque that might indicate higher risk. They will also check how well any treated blood vessels are healing and whether participants are taking their medication as prescribed. The study will last for approximately 12 months of treatment for each participant.
Italy 
